TUBITAK Destekli Projelerden Çıkan Yayınlar Topluluğu
Published January 1, 2024 | Version v1
Journal article Open

Developing blood-brain barrier arterial spin labelling as a non-invasive early biomarker of Alzheimer's disease (DEBBIE-AD): a prospective observational multicohort study protocol

Creators

  • 1. Amsterdam UMC, Locatie VUmc, Dept Radiol & Nucl Med, Amsterdam, Netherlands
  • 2. Fraunhofer Inst Digital Med MEVIS, Bremen, Germany
  • 3. Natl Univ Hlth Syst, Singapore, Singapore
  • 4. Univ Oslo, Ctr Lifespan Changes Brain & Cognit, Oslo, Norway
  • 5. Oslo Univ Hosp, Dept Phys & Computat Radiol, Oslo, Norway
  • 6. Univ Hosp Ghent, Dept Diagnost Sci, Ghent, Belgium
  • 7. Univ Calif Davis, Biomed Engn, Davis, CA USA
  • 8. Amsterdam UMC, Locatie VUmc, Dept Internal Med, Amsterdam, Netherlands
  • 9. Amsterdam UMC, Locatie VUmc, Amsterdam, Netherlands
  • 10. Univ Auckland, Sch Psychol, Auckland, New Zealand
  • 11. Univ Auckland, Dept Pharmacol & Clin Pharmacol, Auckland, New Zealand

Description

Introduction Loss of blood-brain barrier (BBB) integrity is hypothesised to be one of the earliest microvascular signs of Alzheimer's disease (AD). Existing BBB integrity imaging methods involve contrast agents or ionising radiation, and pose limitations in terms of cost and logistics. Arterial spin labelling (ASL) perfusion MRI has been recently adapted to map the BBB permeability non-invasively. The DEveloping BBB-ASL as a non-Invasive Early biomarker (DEBBIE) consortium aims to develop this modified ASL-MRI technique for patient-specific and robust BBB permeability assessments. This article outlines the study design of the DEBBIE cohorts focused on investigating the potential of BBB-ASL as an early biomarker for AD (DEBBIE-AD).Methods and analysis DEBBIE-AD consists of a multicohort study enrolling participants with subjective cognitive decline, mild cognitive impairment and AD, as well as age-matched healthy controls, from 13 cohorts. The precision and accuracy of BBB-ASL will be evaluated in healthy participants. The clinical value of BBB-ASL will be evaluated by comparing results with both established and novel AD biomarkers. The DEBBIE-AD study aims to provide evidence of the ability of BBB-ASL to measure BBB permeability and demonstrate its utility in AD and AD-related pathologies.Ethics and dissemination Ethics approval was obtained for 10 cohorts, and is pending for 3 cohorts. The results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal.

Files

bib-6930b7c8-3a75-44d6-aca9-6b720160b43c.txt

Files (463 Bytes)

Name Size Download all
md5:e5a3b08875e169e2286ea18a9dad6d56
463 Bytes Preview Download